British Biotech licenses ImmunoGen's cancer drug;terminated
Executive Summary
Broadening its cancer platform, British Biotech has licensed exclusive Japanese and European Union rights to ImmunoGen's tumor-activated prodrug, huN901-DM1, for small-cell lung cancer, paying an up-front fee of (uf)$1.5mm, plus royalties on sales in these territories.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice